🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Breast Neoplasms
Clinical trial register · China

Breast Neoplasms Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 21 Beijing 19 Shanghai 9 Changsha 8 Hefei 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company8 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7 Sun Yat-sen University4 Merck Sharp & Dohme LLC3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences3
Site location
Guangzhou21 Beijing19 Shanghai9 Changsha8 Hefei7
All 60 locations
Target enrolment
to

Breast Neoplasms trials in China

64 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
NCT07763587Breast Neoplasms
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
216
Tianjin
2026-08-01
Not yet open
Ultrasound Screening for Early Detection of Breast Cancer in Elderly Women: A Mixed Cluster-Individual RCT
NCT07698366Breast Neoplasms, Early Detection of Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
82,440
Kunshan
2026-07-10
Not yet open
Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
NCT07691333HR+/HER2- Breast Cancer, Breast Neoplasms
DrugsLetrozole·Capecitabine
Fujian Cancer Hospital
Phase 2
35
Fuzhou, Quanzhou
2026-06-30
Recruiting
Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
NCT07702708HR+/HER2- Breast Cancer, Breast Neoplasms
Fujian Cancer Hospital
Observational
100
Fuzhou, Quanzhou, Ningde, Sanming
2026-06-01
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098Breast Neoplasms
DrugsImlunestrant·Goserelin·Tamoxifen
Eli Lilly and Company
Phase 2
600
2026-05-13
Recruiting
Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models
NCT07500428Breast Neoplasms, Breast Diseases, Ultrasonography
Peking Union Medical College Hospital
Observational
1,380
Beijing
2026-03-12
Recruiting
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
NCT07581834Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases
DrugDalpiciclib
Fujian Cancer Hospital
Phase 2
2,000
Fuzhou, Chengdu
2026-01-21
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Anastrozole·Exemestane·Ribociclib
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou
2025-12-22
Recruiting
Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
NCT07264998Breast Neoplasms, Hormone Receptor-Positive Breast Cancer, Abemaciclib, Abemaciclib-related Diarrhea
Hubei Cancer Hospital
Observational
60
Wuhan
2025-12-21
Recruiting
DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes
NCT07263347Breast Neoplasms, Ischemia-Reperfusion Injury, Postoperative Complications, Wound Healing
Hubei Cancer Hospital
Observational
30
Wuhan
2025-12-20
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin
BioNTech SE
Phase 3
558
Changde, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Neijiang
2025-10-30
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
Shanghai
2025-10-22
Not yet open
Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
NCT07162259Breast Neoplasms
Yan Xue
Phase 4
40
Xi'an
2025-10-01
Recruiting
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
NCT07088263Breast Neoplasms
Sun Yat-sen University
Phase 3
192
Guangzhou
2025-09-15
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Beijing, Tianjin
2025-08-06
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
DrugsXeloda·Liposomal doxorubicin·Taxol·Abraxane
Merck Sharp & Dohme LLC
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning
2025-07-21
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Olaparib·Doxorubicin·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Active, closed
Predicting Long-Term Clinical Outcomes in Chinese Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT06856616Breast Neoplasms
The Third Affiliated Hospital of Harbin Medical University
Observational
6,000
Harbin
2025-05-13
Active, closed
Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes
NCT06833723Breast Neoplasms
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Observational
1,000
Hangzhou
2025-04-17
Recruiting
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
NCT07010939Breast Neoplasms, Quality of Life (QOL), Toxicities, Breast Diseases
FangYi
Observational
3,000
Beijing, Shenzhen, Taiyuan
2025-04-07
Recruiting
Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression
NCT06938373Breast Neoplasms
Xiangya Hospital of Central South University
Observational
1,000
Changsha
2025-03-11
Recruiting
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
NCT06567353Breast Neoplasms, Liver Neoplasms, Metastasis
Ruijin Hospital
Not applicable
10
Shanghai
2024-12-09
Recruiting
Target-specific immunoPET Imaging of Breast Cancer
NCT06715826Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
Drugs[18F]F-RESCA-RB14·[18F]F-RESCA-RT4
RenJi Hospital
Phase 1/2
200
Shanghai
2024-09-21
Recruiting
Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
NCT06464913Breast Neoplasms
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
152
Hangzhou
2024-09-01
By invitation
Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients
NCT06405269Breast Neoplasms, Lipid Profile
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2024-05-06
Not yet open
Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment
NCT06234150Breast Neoplasms, Exercise Therapy, Chemotherapy-Related Cognitive Impairment, Cognitive Dysfunction
The First Affiliated Hospital with Nanjing Medical University
Not applicable
90
Nanjing
2024-04-01
Recruiting
Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
NCT06319157Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
94
Guangzhou
2024-03
Recruiting
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
NCT06313463Breast Neoplasms
DrugCapecitabine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
375
Guangzhou
2024-03
Recruiting
A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
NCT06235931Breast Neoplasms
Second Affiliated Hospital of Soochow University
Not applicable
34
Suzhou
2024-02-01
Not yet open
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
NCT06140576Breast Neoplasms
Zhejiang Cancer Hospital
Phase 1/2
58
Hangzhou
2023-11-30
Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT06121570Breast Neoplasms
DrugsTumor-draining lymph node-derived lymphocyte·IL-2·Epirubicin·Doxorubicin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
NCT06121557Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Recruiting
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
NCT05978648Breast Neoplasms
wang shusen
Phase 2
116
Guangzhou
2023-09-20
Recruiting
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT05981014Breast Neoplasms
DrugsTumor-draining lymph node-derived lymphocyte·IL-2·Epirubicin·Doxorubicin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
196
Guangzhou
2023-08-01
Recruiting
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
NCT05981001Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
170
Guangzhou
2023-08-01
Active, closed
Health Belief Model-Based Survey on Breast Self-Examination Awareness and Practice Among Community-Dwelling Middle-Aged and Older Women
NCT07149636Breast Neoplasms, Breast Self-Examination, Cancer Screening, Health Belief Model
Peking Union Medical College Hospital
Observational
3,000
Beijing
2023-06-01
Recruiting
Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
NCT05494502Breast Neoplasms, Mastectomy, Nerve Block, Dexmedetomidine
Peking University First Hospital
Not applicable
1,206
Beijing
2023-05-23
Active, closed
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Breast Cancer
Peking University Cancer Hospital & Institute
Observational
70
Beijing
2023-05-01
Recruiting
Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial
NCT06024187Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
566
Guangzhou
2022-11-23
Active, closed
Efficacy of Acupuncture Treatment for Breast Cancer-associated Insomnia
NCT05510700Breast Neoplasms, Insomnia
Yin Ping
Not applicable
264
Shanghai
2022-10-20
Active, closed
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
NCT05509790Breast Neoplasms
DrugImlunestrant
Eli Lilly and Company
Phase 1
17
Wuhu, Changsha, Nanchang, Shanghai
2022-10-09
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Anastrozole·Exemestane
Eli Lilly and Company
Phase 3
8,000
Anyang, Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang
2022-10-04
Recruiting
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
NCT06591039Breast Neoplasms
Fudan University
Observational
20,000
Shanghai
2022-07-01
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
DrugsUtidelone·Paclitaxel
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Recruiting
A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
NCT05603078Breast Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
102
Beijing
2022-06-21
Active, closed
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
DrugHLX11
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Ma’anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Not yet open
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05172518Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
DrugsMetronomic Capecitabine·Utidelone
Sun Yat-sen University
Phase 3
512
Guangzhou
2022-03-01
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
DrugsPertuzumab·Trastuzumab deruxtecan·Doxorubicin·Trastuzumab
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Active, closed
Robotic-Assisted vs. Endoscopic-Assisted Sentinel Lymph Node Biopsy in Breast Cancer
NCT07741734Breast Neoplasms
Guangzhou Women and Children's Medical Center
Observational
150
Guangzhou
2021-10-01
Active, closed
Robotic-Assisted Versus Endoscopic-Assisted Axillary Lymph Node Dissection in Breast Cancer
NCT07693361Breast Neoplasms
Guangzhou Women and Children's Medical Center
Observational
127
Foshan, Guangzhou
2021-10-01
Recruiting
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
NCT04983121Breast Neoplasms
Shengjing Hospital
Phase 2
30
Shenyang
2021-08-01
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
DrugsXeloda·Liposomal doxorubicin·Taxol·Abraxane
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Recruiting
Neoadjuvant Radiation in Locally Advanced Breast Cancer
NCT05479409Breast Neoplasms
Fudan University
Phase 2
70
Shanghai
2021-03-01
Active, closed
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189Breast Neoplasms
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Active, closed
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
DrugsPF-07220060·Midazolam
Pfizer
Phase 2
362
Beijing, Zhengzhou, Wuhan, Xi’an, Hangzhou
2020-09-23
Recruiting
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
NCT06877416Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms
Sun Yat-sen University
Observational
700
Guangzhou
2020-01-01
Recruiting
Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer
NCT04065321Breast Neoplasms
Shengjing Hospital
Observational
500
Shenyang
2019-10-01
Recruiting
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
NCT05326295Breast Neoplasms, Neoplastic Cells, Circulating, Chemotherapy Effect
Hunan Cancer Hospital
Observational
1,000
Changsha
2019-03-01
Active, closed
Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer
NCT03583580Breast Neoplasms, Neoplasm Recurrence, Local
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
537
Beijing
2018-07-19
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
DrugsAbemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
669
2014-07-22
Rows per page Showing 1–64 of 64
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/breast-neoplasms

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 64 of those studies listing the condition Breast Neoplasms.

How many Breast Neoplasms trials are recruiting in China?

38 of the 64 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 19 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Neoplasms), 64 studies
PhaseStudiesRecruitingShare
Observational181028.1%
Phase 314721.9%
Not applicable11717.2%
Phase 29614.1%
Phase 1649.4%
Phase 1/2436.3%
Phase 2/3111.6%
Phase 4101.6%

Most active sponsors

Lead sponsors with the most studies (Breast Neoplasms)
Lead sponsorStudiesRecruiting
Eli Lilly and Company84
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University77
Sun Yat-sen University43
Cancer Institute and Hospital, Chinese Academy of Medical Sciences31
Fujian Cancer Hospital32
Merck Sharp & Dohme LLC32
Fudan University22
Guangzhou Women and Children's Medical Center20
Hubei Cancer Hospital22
Peking Union Medical College Hospital21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.